Hevascol

Hevascol is a pharmaceutical product containing ethyl esters of iodised fatty acids derived from poppyseed oil. It is supplied in an intra‑arterial and intralymphatic formulation, marketed in the European Union. The preparation is intended for use under professional supervision, and its composition reflects a specialized fatty‑acid ester profile. Clinical data are limited, and the product is classified without a defined drug class at present in the market.

Hevascol is administered via intra‑arterial or intralymphatic routes for investigational or diagnostic purposes related to vascular and lymphatic systems.

- Potentially used as a contrast or tracer agent in angiographic studies. - May be employed in experimental protocols evaluating fatty‑acid metabolism in arterial tissues. - Considered for research on lymphatic drainage and drug delivery mechanisms. - Utilized in pre‑clinical models investigating the effects of iodised fatty‑acid esters on vascular tone. - Applied in certain therapeutic investigations involving localized intra‑arterial administration.

Adverse reactions to Hevascol have been reported in clinical and research settings, ranging from mild to severe.

Common: - Injection site pain, erythema, or mild swelling lasting a few minutes. - Transient flushing, warmth, or tingling sensation in the treated area. - Mild nausea, headache, or dizziness occurring shortly after administration. - Mild transient elevation of serum iodine levels detectable in laboratory tests. - Temporary discoloration or bruising of the skin at the injection site.

Serious: - Allergic hypersensitivity reactions such as urticaria, angioedema, or anaphylaxis. - Acute vascular occlusion, thrombosis, or embolic events at the injection site. - Severe systemic iodine toxicity, potentially leading to thyroid dysfunction or iodism. - Renal impairment or acute kidney injury in patients with pre‑existing kidney disease.

When considering Hevascol, healthcare professionals should observe several precautionary measures to minimize risks and ensure appropriate use.

- Confirm patient’s allergy status to poppyseed oil or related fatty‑acid derivatives before administration. - Assess baseline thyroid function, especially in individuals with known iodine sensitivity or thyroid disorders. - Use only under controlled clinical or research settings with appropriate monitoring equipment. - Avoid administration in patients with active bleeding disorders or uncontrolled hypertension. - Monitor for signs of vascular compromise or embolic phenomena during and after the procedure. - Consider renal function assessment in patients with existing kidney disease. - Document and report any adverse reactions according to local pharmacovigilance guidelines.

Hevascol may interact with other agents administered intravenously, intra‑arterially, or affecting iodine metabolism; awareness of potential interactions is essential.

Avoid: - Concurrent use of iodinated contrast media, which can exacerbate iodine load and thyroid effects. - Co‑administration with anticoagulants or antiplatelet drugs that increase bleeding risk at the injection site.

Use with caution: - Medications that alter lipid metabolism, such as high‑dose omega‑3 fatty acid supplements. - Thyroid hormone replacement therapy, which may be affected by additional iodine exposure. - Renally excreted drugs, since altered kidney function could modify iodine clearance.